Similarly, should application of EGFR block in patients with EGFR amplification or activating mutations be given on the base PTEN alterations, which are frequent in GBM and linked to reduced responsiveness to EGFR inhibitors [110]? This evidence concerns the gene EGFR and glioblastoma.